| these results provide the first evidence showing that an aberrantly decreased expression of SIRT3 occurred in gastric cancer (GC) patients, suggesting that SIRT3 might function as a mitochondrial tumor suppressor in GC. | gastric, |
| Gastric cancer patients with SIRT3 expression have a better prognosis than those without. SIRT3 expression is an independent prognostic marker for overall survival and may act as a tumor suppressor in gastric cancer. | gastric, |
| results highlight the importance of the SIRT3 as a tumor suppressor protein in breast cancer and suggest that SIRT3 may be a potential molecular biomarker to identify high-risk patients across all molecular subtypes of breast cancer. | breast, |
| SIRT3 and SIRT7 possess tumour suppressor properties in the context of pancreatic cancer. | pancreatic, |
| Results elucidated the function of SIRT3 in hepatocellular carcinoma development and suggested that SIRT3 might function as tumor suppressor in hepatocellular carcinoma by targeting PI3K/Akt pathway. | liver, |
| These results identify SIRT3 as a genomically expressed, mitochondria-localized tumor suppressor. | None |
| Studies indicate that sirtuin 3 (Sirt3) as a genomically expressed, mitochondrial localized tumor suppressor. | None |
| SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis.( | None |
| SIRT3 can function as either oncogene or tumor suppressor on influencing cell death by targeting a series of key modulators and their relevant pathways in cancer. [review] | None |